المؤلفون: A. Savinova V., M. Petrova M., N. Shnayder A., E. Bochanova N., R. Nasyrova F., А. Савинова В., М. Петрова М., Н. Шнайдер А., Е. Бочанова Н., Р. Насырова Ф.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 16, No 5 (2020); 852-860 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 5 (2020); 852-860 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: apixaban, pharmacokinetics, pharmacogenetics, effectiveness, safety, CYP3A5, SULT1A1, ABCB1, ABCG2, апиксабан, фармакокинетика, фармакогенетика, эффективность, безопасность

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2316/2065; Bristol-Myers Squibb. Coumadin (warfarin sodium) prescribing information [cited by Sep 19, 2020]. Available from: https://packageinserts.bms.com/pi/pi_coumadin.pdf.; Lip G.Y.H., Banerjee A., Boriani G., et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018;154(5):1121-201. DOI:10.1016/j.chest.2018.07.040.; Рубаненко О.А. Антикоагулянтная терапия у коморбидных пациентов с разными формами фибрилляции предсердий (ретроспективный госпитальный анализ).Сибирское Медицинское Обозрение. 2017;2(104):71-6.; European Medicines Agency. EU summary of product characteristics: Eliquis (apixaban tablets) [cited by Sep 19, 2020]. Available from: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf.; Bristol-Myers Squibb Company PI. Eliquis (apixaban) prescribing information [cited by Sep 19, 2020]. Available from: https://packageinserts.bms.com/pi/pi_eliquis.pdf.; Сычев Д.А., Синицина И.И., Захарова Г.Ю., и др. Практические аспекты применения апиксабана в клинической практике: взгляд клинического фармаколога. Рациональная Фармакотерапия в Кардиологии. 2015;11(2):209-16. DOI:10.20996/1819-6446-2015-11-2-209-216.; Бельдиев С.Н. Практические аспекты применения апиксабана в клинической практике: продолжение темы. Рациональная фармакотерапия в кардиологии. 2015;11(5):543-7. DOI:10.20996/1819-6446-2015-11-5-543-547.; Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.; Карпов Ю.А. Апиксабан: новые возможности профидактики осложнений у больных с фибрилляций предсердий. Атмосфера. Новости Кардиологии. 2013;4:2-8.; Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17. DOI:10.1056/NEJMoa1007432.; Крюков А.В., Сычев Д.А., Андреев Д.А., и др. Особенности фармакокинетики апиксабана у больных в острый период кардиоэмболического инсульта. Рациональная Фармакотерапия в Кардиологии. 2016;12(3):253-9. DOI:10.20996/1819-6446-2016-12-3-253-259.; Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807- 15. DOI:10.1016/S0140-6736(09)62125-5.; Воробьёва Н.М., Панченко Е.П. Апиксабан: новые возможности в лечении венозных тромбоэмболических осложнений. Атмосфера. Новости Кардиологии. 2015;2:10-17.; Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. DOI:10.1056/NEJMoa1302507.; Agnelli G., Buller H.R., Cohen A., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. DOI:10.1056/NEJMoa1207541.; Drugs.com. FDA Approves Eliquis to Reduce the Risk of Stroke, Blood Clots in Patients with NonValvular Atrial Fibrillation [cited by Sep 19, 2020]. Available from: https://www.drugs.com/newdrugs/fda-approves-eliquis-reduce-risk-stroke-blood-clots-patients-non-valvular-atrial-fibrillation-3618.html.; Парфенов В.А., Вербицкая С.В. Вторичная профилактика инсульта при фибрилляции предсердий, применение апиксабана (исследования ARISTOTLE, AVERROES). Неврология, Нейропсихиатрия, Психосоматика. 2014;6(2S):7-14. DOI:10.14412/2074-2711-2014-2S7-14.; Drugs.com. FDA Approves Eliquis to Reduce Risk of Blood Clots Following Hip Or Knee Replacement Surgery [cited by Sep 19, 2020]. Available from: https://www.drugs.com/newdrugs/fda-approveseliquis-reduce-risk-blood-clots-following-hip-knee-replacement-surgery-4019.html.; Drugs.com. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism [cited by Sep 19, 2020]. Available from: https://www.drugs.com/newdrugs/fdaapproves-eliquis-apixaban-deep-vein-thrombosis-pulmonary-embolism-4073.html.; Khalid S., Daw H. The Role of Apixaban in the Treatment of Heparin-Induced Thrombocytopenia. Cureus. 2017;9(7):e1428. DOI:10.7759/cureus.1428.; Мельничук Е.Ю. Перспективные направления лабораторного мониторинга эффективности и безопасности апиксабана и ривароксабана. Бюллетень Северного Государственного Медицинского Университета. 2018;2(41):70-1.; Скрипка А.И., Когай В.В., Листратов А.И., и др. Персонализированный подход к назначению прямых оральных антикоагулянтов: от теории к практике. Терапевтический Архив. 2019;91(7):111-20. DOI:10.26442/00403660.2019.07.000045.; Luettgen J.M., Knabb R.M., He K., et al. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J Enzyme Inhib Med Chem. 2011;26(4):514-26. DOI:10.3109/14756366.2010.535793.; Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost. 2007;5Suppl 1:60- 4. DOI:10.1111/j.1538-7836.2007.02473.x.; Мальченко А.В. Клиническая фармакология апиксабана. Международный Журнал Прикладных и Фундаментальных Исследований. 2014;1(1):88-9.; Jiang X., Crain E.J., Luettgen J.M., et al. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xaactivity in vitro. Thromb Haemost. 2009;101(4):780-2. DOI:10.1160/th08-07-0486.; Frost C., Wang J., Nepal S., et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J ClinPharmacol. 2013;75(2):476-87. DOI:10.1111/j.1365-2125.2012.04369.x.; Frost C., Nepal S,. Wang J., et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76(5):776- 86. DOI:10.1111/bcp.12106.; Byon W., Nepal S., Schuster A.E., et al. Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects. J Clin Pharmacol. 2018;58(7):965-71. DOI:10.1002/jcph.1097.; Vakkalagadda B., Frost C., Byon W., et al. Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016;16(2):119-27. DOI:10.1007/s40256-015-0157-9.; Raghavan N., Frost C.E., Yu Z., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81. DOI:10.1124/dmd.108.023143.; Wang L., Zhang D., Raghavan N., et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.Drug MetabDispos. 2010;38(3):448-58. DOI:10.1124/dmd.109.029694.; Zhang D., He K., Herbst J.J., et al. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013;41(4):827-35. DOI:10.1124/dmd.112.050260.; Song Y., Chang M., Suzuki A., et al. Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. ClinTher. 2016;38(7):1674-85.e1. DOI:10.1016/j.clinthera.2016.05.004.; Song Y., Wang X., Perlstein I., et al. Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. Clin Ther. 2015;37(8):1703-12. DOI:10.1016/j.clinthera.2015.05.497.; He K., Luettgen J.M., Zhang D., et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011;36(3):129- 39. DOI:10.1007/s13318-011-0037-x.; Wang X., Tirucherai G., Marbury T.C., et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56(5):628-36. DOI:10.1002/jcph.628.; Wong P.C., Pinto D.J., Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478-92. DOI:10.1007/s11239-011-0551-3; Wang L., He K., Maxwell B., et al. Tissue distribution and elimination of [14C] apixaban in rats. Drug Metab Dispos. 2011;39(2):256-64. DOI:10.1124/dmd.110.036442.; Frost C., Shenker A., Jhee S., et al. Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. Clin Pharmacol. 2018;10:153-163. DOI:10.2147/CPAA.S169505.; Cui Y., Song Y., Wang J., et al. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol. 2013;5:177-84. DOI:10.2147/CPAA.S51981.; Wang X., Mondal S., Wang J., et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014;14(2):147-54. DOI:10.1007/s40256-013-0055-y.; Frost C.E., Song Y., Shenker A., et al. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet. 2015;54(6):651-62. DOI:10.1007/s40262-014-0228-0.; Upreti V.V., Wang J., Barrett Y.C., et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76(6):908-16. DOI:10.1111/bcp.12114.; Leil T.A., Frost C., Wang X., et al. Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery. CPT Pharmacometrics Syst Pharmacol. 2014;3(9):e136. DOI:10.1038/psp.2014.34.; Cirincione B., Kowalski K., Nielsen J., et al. Population Pharmacokinetics of Apixaban in Subjects WithNonvalvular Atrial Fibrillation. CPT Pharmacometrics Syst Pharmacol. 2018;7(11):728-738. DOI:10.1002/psp4.12347.; Sandhu R.K., Ezekowitz J., Andersson U., et al. The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016;37(38):2869-78. DOI:10.1093/eurheartj/ehw124.; Byon W., Sweeney K., Frost C., Boyd R.A. Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism. CPT Pharmacometrics Syst Pharmacol. 2017;6(5):340-9. DOI:10.1002/psp4.12184.; Goto S., Zhu J., Liu L., et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J. 2014;168(3):303-9. DOI:10.1016/j.ahj.2014.06.005.; Chang M., Yu Z., Shenker A., et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56(5):637-45. DOI:10.1002/jcph.633.; Tirona R.G., Kassam Z., Strapp R., et al. Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. Drug Metab Dispos. 2018;46(5):485-92. DOI:10.1124/dmd.117.079624.; Ueshima S., Hira D., Fujii R., Kimura Y., et al. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics. 2017;27(9):329-36. DOI:10.1097/FPC.0000000000000294.; SNPedia. CYP3A5 [cited by Sep 19, 2020]. Available from: https://www.snpedia.com/index.php/CYP3A5.; Kang R.H., Jung S.M., Kim K.A., et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol. 2009;29(3):272-7. DOI:10.1097/JCP.0b013e3181a289e0.; Umamaheswaran G., Kumar D.K., Adithan C. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective. Indian J Med Res. 2014;139(1):27-65; Canonico M., Bouaziz E., Carcaillon L., et al. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab. 2008;93(8):3082-7. DOI:10.1210/jc.2008-0450.; SNPedia. CYP1A2 [cited by Sep 19, 2020]. Available from: https://www.snpedia.com/index.php/CYP1A2.; Kanuri S.H., Kreutz R.P. Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019; 9(1):7. DOI:10.3390/jpm9010007.; Sweezy T., Mousa S.A. Genotype-guided use of oral antithrombotic therapy: A pharmacoeconomic perspective. Pers. Med. 2014;11:223-35. DOI:10.2217/pme.13.106.; Carlini E.J., Raftogianis R.B., Wood T.C., et al. Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics. 2001;11:57-68. DOI:10.1097/00008571-200102000-00007.; Wang L., Raghavan N., He K., et al. Sulfation of o-DemethylApixaban: Enzyme Identification and Species Comparison. Drug Metab Dispos. 2009;37:802-8. DOI:10.1124/dmd.108.025593.; Nagar S., Walther S., Blanchard R.L. Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol Pharmacol. 2006;69:2084-92. DOI:10.1124/mol.105.019240.; Raftogianis R.B., Wood T.C., Otterness D.M., et al. Phenol SulfotransferasePharmacogenetics in Humans: Association of Common SULT1A1 Alleles with TS PST Phenotype. Biochem Biophys Res Commun. 1997;239:298-304. DOI:10.1006/bbrc.1997.7466.; Dimatteo C., D’Andrea G., Vecchione G., et al. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thromb Res. 2016;145:24-6. DOI:10.1016/j.thromres.2016.07.005.; Xie Q., Xiang Q., Mu G., et al. Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis. Curr Pharm Des. 2018;24(30):3558-65. DOI:10.2174/1381612824666181018153641.; Kryukov A.V., Sychev D.A., Andreev D.A., et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharm Pers Med. 2018;11:43-9. DOI:10.2147/PGPM.S157111.; Cusatis G., Sparreboom A. Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008; 9(8):1005-9. DOI:10.2217/14622416.9.8.1005.; Cusatis G., Gregorc V., Li J., et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. Journal of the National Cancer Institute. 2006;98(23):1739-42. DOI:10.1093/jnci/djj469.; Woodward O.M., Tukaye D.N., Cui J., et al. Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules. Proceedings of the National Academy of Sciences U S A. 2013;110(13):5223-8. DOI:10.1073/pnas.1214530110.; O’Connor C.T., KiernanT.J., Yan B.P. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):725-39. DOI:10.1080/17425255.2017.1338274.; Ueshima S., Hira D., Kimura Y., et al. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018;84(6):1301-12. DOI:10.1111/bcp.13561.; https://www.rpcardio.com/jour/article/view/2316

الاتاحة: https://www.rpcardio.com/jour/article/view/2316
https://doi.org/10.20996/1819-6446-2020-10-17

المؤلفون: A. Usoltseva A., D. Dmitrenko V., S. Zobova N., E. Bochanova N., N. Shnayder A., А. Усольцева А., Д. Дмитренко В., С. Зобова Н., Е. Бочанова Н., Н. Шнайдер А.

المساهمون: Публикация статьи поддержана ООО «ЮСБ Фарма».

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 11, No 4 (2019); 68-76 ; Неврология, нейропсихиатрия, психосоматика; Vol 11, No 4 (2019); 68-76 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2019-4

مصطلحات موضوعية: levetiracetam, epilepsy, pharmacogenetics, aggressivity, impulsivity, DRD2, DBH, COMT, леветирацетам, эпилепсия, фармакогенетика, агрессивность, импульсивность

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1212/966; Helmstaedter C, Mihov Y, Toliat MR, et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia. 2013; 54(1):36-44. doi:10.1111/j.1528-1167.2012.03603.x; Карлов ВА, Власов ПН, Жидкова ИА. Открытое проспективное клиническое исследование эффективности и переносимости препарата леветирацетам в монотерапии фокальной эпилепсии у взрослых при применении референтной и воспроизведенной форм препарата. Неврология, нейропсихиатрия, психосоматика. 2018; (спецвыпуск 1): 12-17 doi:10.14412/2074-2711-2018-1S-12-17; Deshpande LS, DeLorenzo RJ. Mechanisms of Levetiracetam in the control of status epilepticus and epilepsy. Front Neurol. 2014; 5(11): 1-5. doi:10.3389/fneur.2014.00011; Бочанова ЕН, Шнайдер НА, Дмитренко ДВ и др. Сравнительная оценка частоты аггравации эпилептических припадков на фоне приема противоэпилептических препаратов различных поколений. Фарматека. 2017; 9:56-60; Бочанова ЕН, Шнайдер НА, Зырянов СК и др. Возрастные и гендерные аспекты нежелательных побочных реакций у пациентов с эпилепсией и эпилептическими синдромами (по данным регистра Университетской клиники). Фарматека. 2016; 20(7): 71-75; Craig I, Halton K. Genetics of human aggressive behavior. Hum Genet. 2009; 126: 101-113. doi:10.3389/fneur.2018.00905; Gong P, Liu J, Li S, et al. Dopamine betahydroxylase gene modulates individuals’ empathic ability. Social Cognitive and Affective Neuroscience. 2014; 9(9):1341-5. doi:10.1093/scan/nst122; Stelzel C, Basten U, Montag C, et al. Frontostriatal involvement in task switching depends on genetic differences in d2 receptor density. J Neurosci. 2010; 30:14205-12. doi:10.1523/JNEUROSCI.1062-10.2010; Savitz J, Hodgkinson CA, Martin-Soelch C, et al. DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder. Int J Neuropsychopharmacol. 2013; 16(9):2095-101. doi:10.1017/S146114571300045X; Циркин ВИ, Багаев ВИ, Бейн БН. Роль дофамина в деятельности мозга (обзор литературы). Вятский медицинский вестник. 2010; 1:7-18; Arias-Carrion O, Stamelou M, MurilloRodriguez E, et al. Dopaminergic reward system: a short integrative review. International Archives of Medicine. 2010; 3(24):1-6. doi:10.1186/1755-7682-3-24; Brodie MJ, Besag F, Ettinger AB, et al. Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev. 2016; 68:563-602. doi:10.1124/pr.115.012021; Bozzi Yu, Borrelli E. The role of dopamine signaling in epileptogenesis. Frontiers in cellular neuroscience. 2013; 7:157. doi:10.3389/fncell.2013.00157; Hess C, Reif A, Strobel A, et al. A functional dopamine-beta-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders. J Neural Transm. 2009; 116(2): 121-30. doi:10.1007/s00702-008-0138-0; Анохина ИП, Веретинская АГ, Кузнецова МН и др. Активность дофамин-бета-гидроксилазы и 1021 C/T полиморфизм еe гена у больных алкоголизмом. Вопросы наркологии. 2009; 4:57-65; Шкловский ВМ, Вильянов ВБ, Ременник АЮ и др. Взаимодействие полиморфизмов rs1800497 ANKK1 и rs2075654 DRD2 у больных с ишемическим и геморрагическим инсультом. Вестник восстановительной медицины. 2014; 3:117-118; Wakita M, Kotani N, Kogure K, et al. Inhibition of excitatory synaptic trans-mission in hippocampal neurons by Levetiracetam involves Zn2+-dependent GABAA receptormediated presynaptic modulation. J Pharmacol Exp Ther. 2014; 348(2):246–59. doi:10.1124/jpet.113.208751; Fukuyama K, Tanahashi S, Nakagawa M, et al. Levetiracetam inhibits neurotransmitter release associated with CICR. Neurosci Lett. 2012; 518:69–74. doi:10.1016/j.neulet.2012.03.056; Du H, Nie S, Chen G, et al. Levetiracetam ameliorates L-DOPA-induced dyskinesia in hemiparkinsonian rats inducing critical molecular changes in the striatum. Parkinson’s Dis. 2015; 2015:253878. doi:10.1155/2015/253878; https://nnp.ima-press.net/nnp/article/view/1212

الاتاحة: https://nnp.ima-press.net/nnp/article/view/1212
https://doi.org/10.14412/2074-2711-2019-4-68-76

المؤلفون: E. Bochanova N., Е. Бочанова Н.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 11, No 1 (2015); 92-95 ; Рациональная Фармакотерапия в Кардиологии; Vol 11, No 1 (2015); 92-95 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2015-11-1

مصطلحات موضوعية: pharmacokinetics, dosage regimen, new oral anticoagulants, фармакокинетика, режим дозирования, новые пероральные антикоагулянты

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/66/73; Belousov YB, Kukes VG, Lepahin VK, Petrov VI, eds. Clinical pharmacology. National guidance. Moscow: GEOTAR-Media; 2014. Russian (Белоусов Ю.Б., Кукес В.Г., Лепахин В.К., Петров В.И., редакторы. Клиническая фармакология. Национальное руководство. М.: Гэотар-Медиа; 2014).; Clemens A, Haertter S, Friedman J, et al. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin 2012;28:195-201; Belousov YB, Leonova MV, eds. Fundamentals of clinical pharmacology and rational pharmacotherapy: A Guide for practitioners. Moscow: Litterra; 2002. Russian (Белоусов Ю.Б., Леонова М.В., редакторы. Основы клинической фармакологии и рациональной фармакотерапии: Руководство для практикующих врачей. М.: ЛитТерра; 2002); Comté L1, Vrijens B, Tousset E, et al. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn 2007;34(4):549-58.; Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-74.; Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013;11:1295-9.; Reshet'ko OV, Lutsevich KA, Ardentova NN, Lutsevich TS. Lack of adherence to treatment as a problem of rational pharmacotherapy. Klinicheskaya Farmakologiya i Terapiya 2010; 19 (2): 75-80. Russian (Решетько О.В., Луцевич К.А., Ардентова Н.Н, Луцевич Т.С. Отсутствие приверженности к лечению как проблема рациональной фармакотерапии. Клиническая Фармакология и Терапия 2010; 19 (2): 75-80); Eriksson B Dahl OE, Büller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3(1):103-11.; Sairaku A, Yoshida Y, Ando M, A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation. Clin Drug Investig 2013;33(11):847-53.; https://www.rpcardio.com/jour/article/view/66

الاتاحة: https://www.rpcardio.com/jour/article/view/66
https://doi.org/10.20996/1819-6446-2015-11-1-92-95